New study aims to predict immunotherapy success in liver cancer patients

NCT ID NCT07623265

Recruiting now Knowledge-focused Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

First seen Jun 12, 2026 · Last updated Jun 12, 2026

Summary

This study focuses on liver cancer patients and aims to personalize their treatment. Researchers will use lab tests on tumor tissue and blood to find out which patients are likely to benefit from immunotherapy before starting treatment. This way, patients who won't respond can avoid side effects and try other therapies instead. The study involves 300 participants and is currently recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AZ Delta
RECRUITING

Roeselare, Belgium

Contact Email: •••••@•••••

Contact
AZ Groeninge
RECRUITING

Kortrijk, Belgium

Contact Email: •••••@•••••

Contact
Jessa ziekenhuis
RECRUITING

Hasselt, Belgium

Contact Email: •••••@•••••

Contact
UZA
RECRUITING

Antwerp, Belgium

Contact Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

HEPATOCELLULAR CARCINOMA (HCC)